000			01377nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aPersonalized Medicine in Oncology
546			_aEnglish[eng]
650			_apatient-derived tumor xenograft (PDX)||anti-cancer drug development||immunodeficient mice||precision medicine||molecular profiling||immunohistochemistry||next-generation sequencing||targeted therapy||molecular oncology||biomarkers||molecular imaging||non-small cell lung cancer||proliferation||cancer stem cells||circulating tumour cells||personalised treatment||renal cell carcinoma||clear cell||VEGF||immunotherapy||PD-L1||immune checkpoint inhibitors||immune checkpoint blockade||tyrosine-kinase inhibitors||integrin-linked kinase (ILK)||ovarian cancer||sgRNA||gene expression||microarray||xenograft||MTB||cancer||oncology practice||community setting||CGP||pancreatic cancer||FOLFIRINOX||chemotherapy||gender||cholangiocarcinoma||biliary tract cancer||prognosis||neutrophils||BRCA1||BRCA2||PALB2||homologous recombination repair||colorectal cancer||heme oxygenase-1||endothelin-1||endothelin con-verting enzyme-1||bosentan||precision oncology||tumor-agnostic indications||solid tumors||tumor markers||FDA-approved therapeutics||n/a
700			_aVanderWalde, Ari
856			_uhttps://mdpi.com/books/pdfview/book/4866
942			_cEB
999			_c24004 _d24004